Nudging up the valuation by 140p to 7,260p each, the bank said the main oncology pillars of the group – Lynparza, Tagrisso and Imfinzi – showed robust growth in the third quarter.
It also cited “vaccine news flow tailwinds” as a potential further driver of financial success for the Anglo-Swedish giant.
Pfizer and BioNTech have come forward with what looks like the world’s first effective Covid vaccine.
However, they are expected to be the first of a whole line of life sciences companies to come forward with potential inoculations – working on a jab is AZ, which is developing the drug in collaboration with the University of Oxford.
Experts believe a number of approaches will be required to defeat coronavirus, while governments have pre-ordered supplies from multiple different sources, including AstraZeneca.
So, being the second-, or third-mover in the space – so long as the vaccine proves effective – could easily still result in the company being one of the pandemic success stories.
The stock, up 40% from its late-March low, was changing hands for 8,731p, up 2.3% on the day